What Sonio Announced About Its Suspect Integration Configuration Clearance

Sonio said on 24 June 2026 that the FDA cleared the Sonio Suspect Integration Configuration under K261519, a version of its abnormal fetal finding detection that can be built into an ultrasound machine instead of running only as a standalone web application. The company says it keeps working where computing power is limited, calls it the first AI cleared as an integration module in an ultrasound machine for anomaly detection, and describes it as its fifth FDA clearance in under three years.

Why the Sonio Embedded Clearance Matters to Ultrasound Buyers

Running inside the scanner removes the second screen and the network dependency, which is the part that usually kills imaging AI in a busy clinic or a site with thin bandwidth. It also makes the software something a machine maker can ship, and Samsung owns Sonio, so a buyer should ask which scanners the module will actually reach. The clearance covers this configuration, not a new claim about how well the detection works, so the performance question is still the earlier evidence.

Where the Sonio Update Comes From

Sonio is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

Sonio original source.

How We Would Research the Sonio Embedded Clearance

The source gives us the starting point. This is how we would build the next layer of research around it.

  1. We would start with the K261519 summary and read whether the indications for use differ between the embedded and the web version.
  2. Then we would ask Sonio which third-party ultrasound systems the module is cleared and supported on, rather than which it could run on.
  3. We would ask what happens to the detection when the machine is older or the computing power is lower, since that is the trade the announcement is built around.